癌症靶向药能活几年 我国食药监局批准肺癌新药泰瑞沙

我国食药监局批准肺癌新药泰瑞沙  

The London stock market listed pany AstraZeneca announced that the China Food and Drug Administration (CFDA) has granted marketing authorization for its lung cancer pill Tagrisso in China.
Tagrisso (osimertinib) is designed for the treatment of adult lung cancer patients with certain geic mutations

It is the first AstraZeneca medicine approved under the CFDA's Priority Review pathway
using an accelerated timeline for an innovative medicine.
这是阿斯利康经中国国家食药监总局优先审批制度获批的首款药物，该制度缩短了创新药的审批时限。
Sean Bohen
executive vice-president of global medicines development and chief medical officer at AstraZeneca
said: "This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with non-small cell lung cancer in China
where epidermal growth factor receptor mutation rates are some of the highest in the world."
According to the pany
the rapid review and approval signal the urgent need for new
targeted treatments with the potential to address specific types of cancer with high incidence rate and significant unmet medical need in China.